Media

Here you will find our latest & archived press releases and our corporate brand guidelines.

Press Releases

Press ReleaseDate
Sun Pharma geared to introduce Molnupiravir, licensed from MSD and Ridgeback, under the brand name Molxvir® in IndiaNovember 11, 2021
Q2 FY22 Financial Press ReleaseNovember 2, 2021
Sun Pharma Announces Availability of WINLEVI® (clascoterone) cream 1% in the U.S. for Topical Treatment of Acne VulgarisNovember 1, 2021
Sun Pharma’s ILUMYA™ (tildrakizumab injection) now available to help Canadians living with moderate-to-severe plaque psoriasisOctober 28, 2021
Sun Pharma to announce second quarter results on November 02, 2021October 19, 2021
Sun Pharma launches Chericof® 12 in India, a novel formulation that provides relief from cough for up to 12 hoursSeptember 28, 2021
Sun Pharma forays into Nutrition Bar segment with the launch of Revital NXTSeptember 08, 2021
Sun Pharma and Cassiopea announce the expiry of the HSR Act process and the successful consummation of their Winlevi® (clascoterone cream 1%) agreementAugust 31, 2021
Q1 FY22 Financial Press ReleaseJuly 30, 2021
Sun Pharma and Cassiopea SpA Announce Signing of License and Supply Agreements for Winlevi® (clascoterone cream 1%) in US and CanadaJuly 26, 2021
Sun Pharma to announce first quarter results on July 30, 2021July 16, 2021
Sun Pharma launches ‘Sunkalp’ on the occasion of National Doctors’ DayJuly 01, 2021
Press Release Pharma Majors Collaborate for Clinical Trial of Anti Viral Drug Molnupiravir for COVID-19June 29, 2021
Press Release Settlement of Patent Litigation for Generic Revlimid in USJune 22, 2021
Sun Pharma and Ferring Pharmaceuticals enter into licensing agreement for introducing CARITEC® in IndiaJune 02, 2021
Q4 FY21 Financial Press ReleaseMay 27, 2021
Sun Pharma Q4 FY21 financial result on May 27, 2021May 12, 2021
Sun Pharma signs voluntary licensing agreement with Eli Lilly for expanding access to Baricitinib to help alleviate the burden of Covid-19 in IndiaMay 10, 2021
Sun Pharma Launches Website for its Long Term Care Portfolio in the USFebruary 25, 2021
Sun Pharma to introduce complete range of Brivaracetam at an affordable price for epilepsy treatment in IndiaFebruary 23, 2021
SPIL Q3FY21 Financials ResultsJanuary 29, 2021
Sun Pharma’s financials for Q3 and nine month period ending December 31, 2020January 29, 2021
Sun Pharma to announce third quarter results on January 29, 2021January 04, 2021
Sun Pharma announces initiation of Phase 2 Clinical Trial of SCD-044 in Patients with Moderate to Severe Plaque PsoriasisJanuary 04, 2021
Press ReleaseDate
FY21 Q2 Financial Press ReleaseNovember 03, 2020
FY21 Q2 Financial ResultsNovember 03, 2020
Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA® in Patients with Moderate-to-Severe Plaque PsoriasisOctober 31, 2020
Sun Pharma to announce Second quarter results on November 03, 2020October 22, 2020
Press Release Sun Pharma announces the launch of ILUMYA for treatment of plaque psoriasis in JapanSeptember 23, 2020
FY21 Q1 Financial Result - TranscriptAugust 26, 2020
Sun Pharma launches FluGuard® (Favipiravir) in India at Rs. 35 per tabletAugust 04, 2020
FY21 Q1 Financial Press ReleaseJuly 31, 2020
FY21 Q1 Financial ResultsJuly 31, 2020
Sun Pharma launches ‘Thank you Doctor’ campaignJuly 09, 2020
FY20 Q4 Financial Result - TranscriptJuly 06, 2020
Sun Pharma announces Japan MHLW approval of ILUMYA for the treatment of Plaque PsoriasisJune 29, 2020
Sun Pharma Announces Pre-Clinical Data on GL0034June 24, 2020
Sun Pharma and Hikma enter into exclusive licensing agreement for ILUMYA™ for Middle East & North Africa regionsJune 15, 2020
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA TMJune 13, 2020
Sun Pharma Presents ODOMZO® and LEVULAN® KERASTICK® + BLU-U® Data, Offering Clinical Insights for Treating People with or at Risk of Skin CancerJune 13, 2020
Sun Pharma initiates Phase II clinical trial on AQCH, a phytopharmaceutical drug, as potential treatment for COVID-19 patientsJune 05, 2020
Sun Pharma receives approval from DCGI to initiate clinical trial with Nafamostat in Covid 19 patientsMay 29, 2020
Sun Pharma and SPARC enter into a worldwide license agreement for SCD 044May 28, 2020
Sun Pharma Q4FY20 Financial ResultsMay 27, 2020
FY20 Q4 Financial Press ReleaseMay 27, 2020
FY20 Q4 Financial ResultsMay 27, 2020
Sun Pharma to announce fourth quarter results on May 27, 2020May 19, 2020
FY20 Q3 Financial Result - TranscriptApril 09, 2020
Sun Pharma Commits Donation of Medicines and Hand Sanitizers to Support India’s COVID-19 Pandemic ResponseMarch 27, 2020
SPII Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 TreatmentMarch 27, 2020
FY20 Q3 Financial ResultsFebruary 06, 2020
FY20 Q3 Financial Press ReleaseFebruary 06, 2020
Sun Pharma Introduces ABSORICA LD™ Capsules for Management of Severe Recalcitrant Nodular Acne in the U.S.February 04, 2020
Sun Pharma to announce third quarter results on 06 February 2020January 20, 2020
Sun Pharma and Rockwell Medical enter into licensing agreement for Triferic in IndiaJanuary 15, 2020
Press ReleaseDate
FY20 Q2 Financial Result - TranscriptDecember 10, 2019
FY20 Q2 Financial ResultsNovember 07, 2019
FY20 Q2 Financial Press ReleaseNovember 07, 2019
Sun Pharma and AstraZeneca enter into License Agreement for Novel Oncology products in ChinaNovember 06, 2019
Sun Pharma to announce second quarter results on 07 November 2019October 24, 2019
Sun Pharma Launches Drizalma Sprinkle in the USOctober 16, 2019
Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the USOctober 14, 2019
Malaria Elimination Programme Receives Mahatma Award for Social GoodOctober 10, 2019
Sun Pharma Presents Long-term Study Results that Show Significant Skin Clearance with ILUMYAOctober 09, 2019
FY20 Q1 Financial Result - TranscriptOctober 03, 2019
Sun Pharma and China Medical System Holdings Enter into Licensing Agreement for Generic Products in Mainland ChinaAugust 16, 2019
Sun Pharma and China Medical System Holdings Enter into Licensing Agreement for Generic Products in Mainland ChinaSun Pharma Announces Licensing Agreement With CSIR-IICTAugust 14, 2019
FY20 Q1 Financial ResultsAugust 13, 2019
FY20 Q1 Financial Press ReleaseAugust 13, 2019
Sun Pharma to announce first quarter results on August 13, 2019August 05, 2019
Sun Pharma Announces Regulatory Filing of Tildrakizumab in JapanAugust 01, 2019
Sun Pharma Launches Ezallor Sprinkle (Rosuvastatin) in the U.S. for People Who Have Difficulty SwallowingJuly 15, 2019
Sun Pharma and China Medical System Holdings enter into a License Agreement for Tildrakizumab in Greater ChinaJune 27, 2019
Sun Pharma and China Medical System Holdings enter into a License Agreement for Cyclosporine A eye drops in Greater ChinaJune 27, 2019
Late Breaking Phase 2 Data Showing Potential of ILUMYA for Psoriatic ArthritisJune 14, 2019
FY19 Q4 Financial ResultsMay 28, 2019
FY19 Q4 Financial Press ReleaseMay 28, 2019
Sun Pharma to announce fourth quarter results on May 28, 2019May 14, 2019
Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S.April 08, 2019
FY19 Q3 Financial Result - TranscriptMarch 08, 2019
ILUMYA 3 Year Data Demonstrates Sustained Skin Clearance in Patients with Moderate to Severe Plaque PsoriasisMarch 01, 2019
FY19 Q3 Financial Press ReleaseFebruary 12, 2019
Sun Pharma Q3 FY19 financial result on 12 February 2019January 28, 2019
Press Release Sun Pharma Investor UpdateJanuary 22, 2019
Press ReleaseDate
Investor Update Call TranscriptDecember 27, 2018
DUSA Pharmaceuticals, Inc. Awarded Preliminary Injunctive Relief Prohibiting Biofrontera From Using Its Trade SecretsDecember 26, 2018
Clarification on recent media reportsDecember 03, 2018
Sun Pharma Announces US FDA Approval For Generic Ganirelix Acetate InjectionDecember 03, 2018
Sun Pharma to hold an Investor Update Call on 03 December 2018December 03, 2018
Sun Pharma to acquire Pola Pharma in JapanNovember 26, 2018
FY19 Q2 Financial Result - TranscriptNovember 20, 2018
FY19 Q2 Financial Press ReleaseNovember 13, 2018
Sun Pharma Announces the Availability of ILUMYA in the United StatesOctober 23, 2018
Sun Pharma to announce second quarter results on 13 November 2018October 23, 2018
Sun Pharma announces Australian TGA approval of ILUMYASeptember 21, 2018
Sun Pharma Announces Receipt of European Commission Approval For ILUMETRISeptember 18, 2018
Sun Pharma and SPARC Announce US FDA Approval of XELPROSSeptember 14, 2018
Clarification to Stock Exchanges on Mohali facilitySeptember 11, 2018
Clarification to Stock Exchanges on news regarding Halol facilitySeptember 07, 2018
FY19 Q1 Financial Result - TranscriptSeptember 04, 2018
Sun Pharma launches Volini Maxx, India’s Strongest Pain Relief SprayAugust 29, 2018
Sun Pharma Announces USFDA Approval of CEQUA to Treat Dry Eye DiseaseAugust 16, 2018
FY19 Q1 Financial Press ReleaseAugust 14, 2018
Sun Pharma Launches Novel Drug Kapspargo Sprinkle™ in USAAugust 06, 2018
Sun Pharma to announce first quarter results on 14 August 2018July 27, 2018
Sun Pharma Announces Launch of Generic Glumetza® Tablets in USJuly 25, 2018
Sun Pharma Announces USFDA Approval of INFUGEM InjectionJuly 18, 2018
DUSA Pharmaceuticals, Inc. files lawsuit against Biofrontera Inc.July 11, 2018
Sun Pharma signs Akshay Kumar as Revital H Brand AmbassadorJuly 09, 2018
Sun Pharma receives EIR for Halol facilityJune 12, 2018
Clarification on news regarding HalolJune 08, 2018
FY18 Q4 Financial Result - TranscriptJune 08, 2018
FY18 Q4 Financial Press ReleaseMay 25, 2018
Sun Pharma Announces USFDA Approval of YONSAMay 23, 2018
Sun Pharma Announces US Launch of Authorized Generic for Welchol TabletsMay 17, 2018
Sun Pharma to announce fourth quarter results on 25 May 2018May 11, 2018
Sun Pharma CHC enters anti fungal powder OTC category with ABZORBApril 30, 2018
FDEC First Year Report of Malaria Elimination Demonstration Project (MEDP)March 23, 2018
Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn)March 21, 2018
ILUMYA™ U.S. Prescribing InformationMarch 21, 2018
ILUMYA™ U.S. Medication GuideMarch 21, 2018
FY18 Q3 Financial Press ReleaseFebruary 14, 2018
Sun Pharma Science Foundation's Annual Conference and Research Awards Presentation CeremonyFebruary 13, 2018
Sun Pharma to announce third quarter results on February 14, 2018February 02, 2018
Sun Pharma Announces Settlement of Patent Litigation for Generic Linzess in USJanuary 16, 2018
Press ReleaseDate
Sun Pharma Announces US FDA Acceptance of NDA for OTX-101December 27, 2017
FY18 Q2 Financial Result - TranscriptDecember 02, 2017
Sun Pharmaceutical Industries Inc. Issues Voluntary Nationwide Recall of Riomet®November 24, 2017
FY18 Q2 Financial Press ReleaseNovember 14, 2017
Sun Pharma to announce second quarter results on November 14, 2017October 31, 2017
Sun Pharma announces US FDA approval for generic Coreg CR®October 26, 2017
Sun Pharma Odomzo® (Sonidegib) New Label ApprovalSeptember 20, 2017
FY18 Q1 Financial Result - TranscriptSeptember 15, 2017
FY18 Q1 Financial Press ReleaseAugust 11, 2017
Sun Pharma to announce first quarter results on August 11, 2017July 26, 2017
Sun Pharma and Samsung BioLogics announce strategic manufacturing tie up for TildrakizumabJuly 04, 2017
Sun Pharma and NIV sign agreement to fight Zika, Chikungunya and DengueJune 27, 2017
US FDA approval for generic Zetia® tabletsJune 13, 2017
FY17 Q4 Financial Result - TranscriptJune 13, 2017
FY17 Q4 Financial Press ReleaseMay 26, 2017
US FDA Filing Acceptance of Biologics License Application For TildrakizumabMay 24, 2017
Sun Pharma to announce fourth quarter results on May 26, 2017May 15, 2017
Sun Pharma Science Foundation recognizes Indian scientists & young research scholarsApril 28, 2017
FDEC commences roll-out of Malaria demonstration projectApril 25, 2017
Sun Pharma Science Foundation Media InvitationApril 25, 2017
Almirall and Sun Pharma Announce Regulatory Filing of Tildrakizumab in EuropeMarch 24, 2017
Update on Mohali FacilityMarch 14, 2017
Tildrakizumab Clinical Development Program to be Presented at the 2017 American Academy of Dermatology MeetingMarch 01, 2017
FY17 Q3 Financial Result - TranscriptFebruary 27, 2017
FY17 Q3 Financial Press ReleaseFebruary 14, 2017
Sun Pharma Q3 FY17 financial result on February 14, 2017January 31, 2017
Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera™ for Treatment of Dry EyeJanuary 04, 2017
Press ReleaseDate
Sun Pharma & Moebius Medical sign deal to develop novel liposomal non-opiod pain product for osteoarthritisDecember 12, 2016
FY17 Q2 Financial Result - TranscriptNovember 30, 2016
Sun Pharma launches first branded ophthalmic product, BromSite in USANovember 28, 2016
Sun Pharma to acquire Biosintez in RussiaNovember 23, 2016
ICMR, Govt of MP and FDEC-India sign tri-party agreement to launch Malaria Free India demonstration project in Mandla district of Madhya Pradesh- English Press ReleaseNovember 15, 2016
ICMR, Govt of MP and FDEC-India sign tri-party agreement to launch Malaria Free India demonstration project in Mandla district of Madhya Pradesh- Hindi Press ReleaseNovember 15, 2016
FY17 Q2 Financial Press ReleaseNovember 10, 2016
Sun Pharma Announces US Launch of Authorized Generics for OlmesartanOctober 27, 2016
Sun Pharma Q2 FY17 financial result on November 10, 2016October 26, 2016
Sun Pharma to Acquire Ocular TechnologiesOctober 26, 2016
Sun Pharma & ICGEB announce new exclusive collaboration to develop novel dengue vaccine for India & Global marketsOctober 19, 2016
Revital H Woman launches ‘Healthy Conversations’ initiativeOctober 03, 2016
Sun Pharma to Announce Late-Breaking Results for TildrakizumabOctober 01, 2016
Sun Pharma announces distribution alliance with Mitsubishi Tanabe Pharma Corporation in JapanSeptember 06, 2016
FY17 Q1 Financial Result - TranscriptAugust 29, 2016
FY17 Q1 Financial Press ReleaseAugust 12, 2016
Sun Pharma extends Imatinib Mesylate Savings Card program benefits for patients in USAAugust 08, 2016
Sun Pharma announces US FDA approval for generic Glumetza®August 02, 2016
Sun Pharma to announce first quarter results on August 12, 2016August 01, 2016
Sun Pharma and Almirall enter into a License Agreement for Tildrakizumab in Europe for PsoriasisJuly 27, 2016
Sun Pharma announces US FDA approval for generic Crestor®July 20, 2016
SPARC licenses Elepsia XR to Sun PharmaJuly 18, 2016
Sun Pharma launches Gemcitabine InfuSMARTJuly 11, 2016
Sun Pharma Announces Buyback of Equity SharesJune 23, 2016
FY16 Q4 Financial Result - TranscriptJune 10, 2016
Sun Pharma focuses on dermatology as additional engine of growth for GCH business-Press ReleaseJune 08, 2016
Sun Pharma focuses on dermatology as additional engine of growth for GCH business-FactsheetJune 08, 2016
Press Conference InvitationJune 06, 2016
Sun Pharma announces divestment of US manufacturing unitsJune 04, 2016
FY16 Q4 Financial Press ReleaseMay 30, 2016
Sun Pharma to announce fourth quarter results on May 30, 2016May 19, 2016
Sun Pharma leverages mobile technology to boost treatment compliance amongst asthma patientsMay 09, 2016
Sun Pharma Announces Positive Results of Two Pivotal Phase-3 Clinical Trials of Tildrakizumab in Patients with Moderate-to-Severe Plaque PsoriasisMay 04, 2016
ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of DengueMay 04, 2016
ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue - Endorsements May 04, 2016
ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue -Dengue Factsheet May 04, 2016
Media Invitation - Signing of Novel Drug Development Agreement, May 4, 2016 April 29, 2016
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Press Release- Malaria Free India April 25, 2016
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Malaria Free India public-private-partnership receives global recognitionApril 25, 2016
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Malaria Free India Blue PrintApril 25, 2016
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Malaria FactsheetApril 25, 2016
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Spokesperson BiosApril 25, 2016
Press Conference Invitation, April 25, New DelhiApril 21, 2016
Sun Pharma Receives USFDA Approval For BromSite™April 09, 2016
Sun Pharma enters Japanese prescription marketMarch 29, 2016
Sun Pharma and AstraZeneca India enter partnership in Type 2 diabetesMarch 23, 2016
Video Release - Digital launch of Pepmelt antacid campaignMarch 11, 2016
Note on Digital launch of Pepmelt antacid campaignMarch 11, 2016
Sun Pharma Consumer Healthcare Business enhances presence in digestive careMarch 11, 2016
Sun Pharma Global Consumer Healthcare signs Indian cricket captain MS Dhoni as Revital H brand ambassadorMarch 08, 2016
FY16 Q3 Earnings Call TranscriptFebruary 26, 2016
FY16 Q3 Financial Press ReleaseFebruary 12, 2016
Sun Pharma launches Imatinib Mesylate in USAFebruary 01, 2016
Sun Pharma to announce third quarter results on February 12, 2016January 30, 2016
Revital H announces association with Patna Pirates, Kabbadi Team as Official Health PartnerJanuary 27, 2016
Transcript - Update on Halol facilityJanuary 04, 2016
Press ReleaseDate
Sun Pharma receives Warning Letter for Halol facilityDecember 19, 2015
Sun Pharma announces divestment of US manufacturing unitDecember 14, 2015
Sun Pharma announces research collaboration with Weizmann Institute of Science, Israel & Health Research Institute of Santiago, Spain for brain therapiesDecember 10, 2015
Sun Pharma announces US FDA approval for generic Gleevec®December 04, 2015
Sun Pharma announces its association with World Champion Snowboarder Kelly Clark for Absorica®December 02, 2015
FY16 Q2 Earnings Call TranscriptNovember 27, 2015
FY16 Q2 Financial Press ReleaseNovember 07, 2015
Sun Pharma Successfully Acquires InSite VisionNovember 03, 2015
Volini announces Sania Mirza and Sunil Chhetri as brand ambassadorsNovember 03, 2015
Sun Pharma completes tender offer for InSite VisionOctober 28, 2015
Sun Pharma Q2 & H1 FY16 financial results on November 07, 2015October 26, 2015
Sun Pharma announces Absorica patent litigation settlementOctober 05, 2015
Sun Pharma commences Tender Offer for Acquisition of InSite VisionSeptember 29, 2015
Strides Arcolab acquires CNS divisions of erstwhile RanbaxySeptember 19, 2015
Sun Pharma to acquire InSite VisionSeptember 15, 2015
Sun Pharma announces successful completion of Opiates business acquisition in AustraliaSeptember 01, 2015
FY16 Q1 Earnings Call TranscriptAugust 25, 2015
Sun Pharma announces US FDA approval for XiminoAugust 19, 2015
FY16 Q1 Financial Press ReleaseAugust 11, 2015
Sun Pharma to announce first quarter results on August 11, 2015July 29, 2015
Transcript - Sun Pharma Business UpdateJuly 24, 2015
Sun Pharma provides business updateJuly 20, 2015
SPARC Licenses XelprosTM (Latanoprost BAK-free) to Sun PharmaJune 09, 2015
Sun Pharma and AstraZeneca enter into distribution agreement for ticagrelor in IndiaJune 02, 2015
Sun Pharma to announce fourth quarter FY15 results on May 29, 2015May 15, 2015
Sun Pharma and the Technion form Research Collaboration to Develop New Class of Oncology DrugsApril 15, 2015
Sun Pharma announces closure of merger deal with RanbaxyMarch 25, 2015
Sun Pharma announces closure of merger deal with Ranbaxy- Profile of Sun PharmaMarch 25, 2015
Sun Pharma announces closure of merger deal with Ranbaxy- Investor Relations Presentation March 25, 2015
Sun Pharma announces closure of merger deal with Ranbaxy- Factsheet March 25, 2015
Sun Pharma announces closure of merger deal with Ranbaxy- Profile of Chairman & MD March 25, 2015
Sun Pharma announces closure of merger deal with Ranbaxy- Growing Together Film March 25, 2015
Press Conference Webcast: Sun Pharma - Ranbaxy MergerMarch 25, 2015
Sun Pharma to buy GSK’s Opiates business in AustraliaMarch 03, 2015
FY15 Q3 Earning Call TranscriptFebruary 24, 2015
Press Release SPIL Financials Q3 FY15February 14, 2015
Sun Pharma to announce third quarter results on February 14, 2015February 09, 2015
Sun Pharma receives US FTC clearance for Ranbaxy acquisitionFebruary 02, 2015
Press ReleaseDate
CCI approves Ranbaxy acquisition by Sun PharmaDecember 08, 2014
Sun Pharma to announce second quarter results on November 13, 2014October 30, 2014
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for TildrakizumabSeptember 17, 2014
Form IV contained in Schedule II to the Combination Regulations under Sec 29(2) of Competition Act, 2002 (as amended)September 04, 2014
Q1 FY15 Earnings Call TranscriptAugust 23, 2014
Q1 FY15 Financial Press ReleaseAugust 12, 2014
Sun Pharma to announce first quarter results on August 12, 2014July 30, 2014
Sun Pharma acquires PharmalucenceJuly 16, 2014
Q4 FY14 Financial Press ReleaseMay 29, 2014
Sun Pharma to announce Q4 and FY14 results on May 29, 2014May 16, 2014
Sun Pharma announces settlement of litigation for generic Gleevec® in USMay 15, 2014
Sun Pharma announces manufacturing consolidationMay 02, 2014
Transcript Sun Pharma - Ranbaxy Merger Conference CallApril 16, 2014
Clarification on Silverstreet Investment in RanbaxyApril 09, 2014
Investor Presentation: Sun Pharma & Ranbaxy mergerApril 07, 2014
Sun Pharma to acquire Ranbaxy in a US$ 4 billion landmark transactionApril 06, 2014
Import Alert for Karkhadi unit from US FDAMarch 13, 2014
FY14 Q3 Earnings call transcriptFebruary 25, 2014
Rekha Sethi appointed as an additional independent director of Sun Pharma BoardFebruary 13, 2014
FY14 Q3 Financial Press ReleaseFebruary 13, 2014
Sun Pharma announces US FDA approval for generic Temodar®February 13, 2014
Sun Pharma to announce third quarter results on February 13, 2014January 29, 2014
Press ReleaseDate
Sun Pharma announces USFDA tentative approval for generic Boniva®December 30, 2010
Sun Pharma announces USFDA tentative approval for generic Aricept®November 30, 2010
Sun Pharma announces USFDA tentative approval for generic Cymbalta®November 24, 2010
Sun Pharma announces USFDA approval for generic Diltiazem ER®November 18, 2010
Sun Pharma announces USFDA approval for generic Clarinex®November 18, 2010
Sun Pharma announces USFDA tentative approval for generic Stalevo®October 01, 2010
Sun Pharma announces USFDA tentative approval for generic Crestor®September 29, 2010
Sun Pharma announces expiration of subsequent offering periodSeptember 29, 2010
Sun Pharma announces USFDA tentative approval for generic Rilutek®September 28, 2010
Sun Pharma acquires controlling stake in TaroSeptember 21, 2010
Sun Pharmaceutical announces expiration of offer for TaroSeptember 15, 2010
Supreme court of Israel rules in favor of Sun PharmaSeptember 07, 2010
Sun Pharma announces USFDA approval for generic Strattera® CapsulesAugust 31, 2010
Sun Pharma subsidiary receives warning letter from USFDAAugust 31, 2010
Sun Pharma announces USFDA approval for generic Venlafaxine ER® TabletsAugust 19, 2010
US appeals court rules Gemzar® patent invalidJuly 29, 2010
Sun Pharma: an update on generic Protonix litigation® July 17, 2010
Sun Pharma announces USFDA approval for generic Flomax®July 16, 2010
US district court rules in favor of Sun Pharmaceutical dismisses all of Taro's claimsJuly 15, 2010
Sun Pharma to announce Q1FY11 results on July 28, 2010July 13, 2010
Sun Pharma: an update on generic Eloxatin® injectionJune 26, 2010
Sun Pharma settles litigation over generic Stalevo® and Comtan®June 22, 2010
Sun Pharma announces USFDA approval for generic Optivar®June 21, 2010
Sun Pharma announces USFDA approval for generic Xanax® TabletsJune 18, 2010
Sun Pharma announces USFDA approval for generic Keppra® Injection, levetiracetam® injectionJune 17, 2010
Sun Pharma: an update on generic Protonix® litigationApril 24, 2010
Sun Pharma announces USFDA tentative approval for generic Namenda® tabletsApril 10, 2010
Sun Pharma announces USFDA approval for generic Wellbutrin® SR extended release tabletsApril 08, 2010
Sun Pharma announces USFDA approval for generic Prometh® syrupMarch 18, 2010
Sun Pharma sends letter to directors of TaroJanuary 11, 2010
Press ReleaseDate
Generic Eloxatin® and Imitrex® approval: shares 180-day marketing drug exclusivity for generic Eloxatin®August 11, 2009
Sun Pharma signs agreement with MedImmune for generic Ethyol®August 03, 2009
Sun Pharma to license key Escitalopram® patent applications to Lundbeck®July 10, 2009
Sun Pharma announces USFDA approval for generic Casodex® tabletsJuly 07, 2009
Conference call transcript - FDA seizure at Caraco, June 2009sJuly 02, 2009
Sun Pharma announces USFDA tentative approval for generic Optivar®July 02, 2009
Sun Pharma to hold conference call on June 27, 2009June 26, 2009
Sun Pharma announces USFDA approval for generic Accupril® tabletsJune 19, 2009
Sun Pharma to announce FY09 results on May 30. Earnings call on June 1, 2009.May 18, 2009
Sun Pharma announces USFDA tentative approval for generic Uroxatral® extended release tablets.May 07, 2009
Sun Pharma announces USFDA approval to market generic Roxicodone® tablets.April 13, 2009
Sun Pharma announces USFDA approval to market generic Topamax® tabletsMarch 28, 2009
Sun Pharma extends tender offer for Taro to April 3, 2009March 20, 2009
Sun Pharma extends tender offer for Taro to Mar 20, 2009March 06, 2009
Sun Pharma extends tender offer for Taro to March 6, 2009January 29, 2009
Sun Pharma Q3 results on Jan 30; conf call on Jan 31January 24, 2009
Sun Pharmaceutical extends tender offer for Taro to January 30, 2009January 07, 2009
Sun Pharma receives USFDA approvals for 4 generic products; company receives its first controlled substance product approvalJanuary 07, 2009
Press ReleaseDate
Sun Pharmaceutical extends tender offer for Taro December 19, 2008January 9, 2009
Sun Pharma update on ANDA for generic Effexor XR: USFDA grants Osmotica's citizen petitionNovember 27, 2008
Sun Pharma subsidiary acquires 100% of Chattem Chemicals, Inc. a US based DEA registered narcotic API importer & producerNovember 25, 2008
Sun Pharmaceutical extends tender offer for Taro to Dec 19, 2008November 07, 2008
Sun Pharmaceutical announces USFDA approval to market generic Sinemet® tabletsNovember 05, 2008
Sun Pharma to announce Q2 and H1 2008-09 results on Oct 25, 2008October 15, 2008
Sun Pharma extends tender offer for TaroOctober 03, 2008
Sun Pharma announces USFDA approval to market generic Paraplatin® injectionSeptember 23, 2008
Sun Pharma gets USFDA approval for generic Fosamax® tabletsSeptember 12, 2008
Sun Pharmaceutical extends tender offer for TaroSeptember 03, 2008
Sun to file amendment to tender offer for Taro waiving certain conditionsAugust 27, 2008
Tel-Aviv court rules in favor of Sun Pharmaceutical; no special tender offer neccessary in Taro offerAugust 27, 2008
Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro’s Irish SubsidiaryAugust 25, 2008
Sun Pharma announces US FTC clearanceAugust 14, 2008
Sun Pharma gets USFDA approval for generic Depakote® delayed release tabletsJuly 30, 2008
Sun Pharma reaffirms commitment to Taro facilities and employeesJuly 28, 2008
Sun Pharma extends tender offer for TaroJuly 14, 2008
Sun Pharma commences tender offer for Taro sharesJune 30, 2008
Sun Pharma exercises its options to acquire the shares of the controlling shareholders of Taro PharmaJune 26, 2008
Sun Pharma comments on Taro's potential sale of its Irish operationsJune 05, 2008
Sun Pharma responds to Taros purported termination of merger agreementMay 29, 2008
Sun Pharma receives notice for termination of merger from TaroMay 28, 2008
Q4 2007-08 results on 30 May, 2008; earnings call on 30 May, 2008 at 6:30 PM ISTMay 17, 2008
Sun Pharmaceutical announces launch of generic Ethyol ® (180 days exclusivity)March 31, 2008
Sun Pharmaceutical announces USFDA approval to market generic Tessalon ®March 21, 2008
Sun Pharmaceutical announces USFDA approval to market generic Cerebyx ®March 19, 2008
Sun Pharmaceutical announces USFDA approval to market generic Ethyol ® (With 180 day marketing exclusivity)March 15, 2008
Sun Pharma gets USFDA tentative approval for generic Gemzar ® injectionMarch 05, 2008
Sun Pharma gets USFDA approval to market generic Demadex ® TabletsFebruary 27, 2008
Sun Pharma buys additional 9.4% stake in Taro Pharma from BrandesFebruary 19, 2008
Sun Pharma gets USFDA tentative approval for generic Depakote ® delayed release tabletsFebruary 14, 2008
Sun Pharma launches generic Protonix ® TabletsJanuary 30, 2008
Sun Pharma Q3 2007-08 results on 30 Jan, 2008; earnings call on January 31, 2008 on 10:00 am ISTJanuary 16, 2008
Press ReleaseDate
Sun Pharma announces settlement of litigation over generic Exelon®December 06, 2007
Sun Pharma announces USFDA approval to market generic Exelon® CapsulesOctober 23, 2007
Sun Pharma receives will-not-sue covenant on generic Effexor XR ® ANDAOctober 16, 2007
Sun Pharma Q2 2007-08 results on Oct 25, 2007; earnings call on Oct 26 at 10 am ISTOctober 09, 2007
Sun Pharma announces USFDA approval to market generic Trileptal® Tablets, 180 day marketing exclusivityOctober 10, 2007
Sun Pharma announces USFDA approval to market generic Protonix Tablets - Company gets its first 180 day marketing exclusivity on a first-to-file ANDA with para IV certificationSeptember 11, 2007
USFDA grants tentative approval for Sun Pharma's ANDA for Galantamine tabletsAugust 30, 2007
Sun Pharma announces USFDA approval for Sinemet CR, an extended release version of Carbidopa with LevodopaAugust 25, 2007
Sun Pharma announces USFDA approval to market generic Octreotide injectionAugust 18, 2007
Investor presentationJuly 26, 2007
Notice of extraordinary general meeting on July 28, 2007July 19, 2007
Sun Pharma to acquire Taro Pharma in a USD 454 million dealMay 21, 2007
Sales growth 30%, profit increased 35%, R&D spend Rs. 2924 millionMay 18, 2007
Apportionment of cost between SPIL and SPARCMay 14, 2007
Way forward on demergerMay 14, 2007
Transcript of management presentation on NCE and NDDSMarch 26, 2007
Management presentation on NCE and NDDSMarch 16, 2007
Announcement of a management presentation on NCE and NDDSMarch 12, 2007
Q3 sales up 27%, net profit up 36%January 29, 2007
3rd Quarter 2006-07 results on 29 Jan 2007, call on 30 Jan at 0930January 15, 2007
Press ReleaseDate
President to inaugurate Sun Pharma's research centerDecember 07, 2004
Sun Pharma declares interim dividendNovember 29, 2004
Sun Pharma completes $275 mill FCCBNovember 27, 2004
Sun Pharma launches $225 mill FCCB IssueNovember 18, 2004
Sun Pharma board to meet on Oct 21: first half resultsOctober 18, 2004
Sun Pharma to buy 3 US brands for $5.4 mill Entry in brand market in North AmericaSeptember 23, 2004
Fire in Unit 1 at PanoliAugust 06, 2004
Sun Pharma: flood at plant sitesAugust 04, 2004
Sun Pharma Q1 post results conference call on Monday, August 2 at 11.00 amAugust 02, 2004
Sun Pharma announces swap ratio for Phlox Pharma mergerJuly 31, 2004
Sun Pharma board to meet July 31: Q1 resultsJuly 19, 2004
Sun Pharma to acquire a bulk active company : Phlox Pharma has EDMF approval, UKMCA / USFDA compliant plantJuly 06, 2004
Fire put out at Sun Pharma's corporate officesJune 21, 2004
Buyback of 6% cumulative redeemable preference sharesMay 27, 2004

Sun Pharma's bulk active and tablet manufacturing factories are cleared by USFDAMay 26, 2004
Letter to the stock exchange for result correctionMay 17, 2004
Record date for bonus is May 29May 06, 2004
No such proposal, says Sun Pharma Bloomberg story titled "Sun Pharma plans to acquire remaining stake in Caraco"April 23, 2004
Sun Pharma Q4 post results conference call on Thursday April 22, 12 noonApril 22, 2004
1:1 Bonus announced exports jumps 48%; powers profit growth PAT up 21.2%, total income up 20.8%, R&D expense 11.7% of turnoverApril 21, 2004

Sun Pharma board to meet April 21: Audited financial resultsApril 13, 2004
Sun Pharma to raise $350mill, EGM announcedApril 08, 2004
Sun Pharma board to meet; to consider issue of convertible debenturesApril 02, 2004
Sun Pharma hikes stake in Caraco to 63.14%"March 13, 2004
Clarification on news items regarding acquisition of HALMarch 09, 2004
Sun Pharma purchases additional stake in Caraco to hold over 60 % equityFebruary 03, 2004
Mr. Ashwin Dani joins Sun Pharma boardFebruary 02, 2004
Q3 results conf call Jan 28/5pm ISTJanuary 28, 2004
Unaudited Q3 numbers on January 28January 19, 2004

Media Contacts

Global Headquarters

Mumbai, India

Gaurav Chugh

Global Communications Lead

(+91 22) 4324 4324 Extn: 5373

gaurav.chugh@sunpharma.com

Top